Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | TYMP | P19971 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9486647 | 0.85 | ALDH1A1 (0.30) | ALDH1A1CYP3A4 | |
| Imidazole SCHEMBL10431351 | 0.82 | ALDH1A1 (0.36) | ALDH1A1CYP3A4ELANE | |
| SCHEMBL2490096 | 0.75 | CA1 (0.39) | ALDH1A1CYP3A4CA1CA9ELANE | |
| SCHEMBL10504263 | 0.74 | ALDH1A1 (0.36) | ALDH1A1CYP3A4ELANETYMPTDP1 | |
| SCHEMBL3233362 | 0.74 | TYMP (0.41) | ALDH1A1CYP3A4ELANETYMPTDP1 | |
| SCHEMBL2105114 | 0.74 | TYMP (0.41) | ALDH1A1CYP3A4ELANETYMPTDP1 | |
| SCHEMBL3502363 | 0.74 | TYMP (0.41) | ALDH1A1CYP3A4ELANETYMPTDP1 | |
| SCHEMBL11201526 | 0.74 | TYMP (0.41) | ALDH1A1CYP3A4ELANETYMPTDP1 | |
| SCHEMBL3233355 | 0.74 | TYMP (0.41) | ALDH1A1CYP3A4ELANETYMPTDP1 | |
| SCHEMBL119773 | 0.74 | TYMP (0.41) | ALDH1A1CYP3A4ELANETYMPTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108530617-B | Branched polyethylene glycol heterobifunctional derivative, preparation method thereof and two-component bio-related substance conjugate thereof | 厦门赛诺邦格生物科技股份有限公司 | 2020-11-27 | — | — | CN | claimed |
| EP-0337697-B1 | USE OF A THROMBOXANE A2 RECEPTOR ANTAGONIST FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING PULMONARY HYPERTENSION CAUSED BY PROTAMINE INDUCED NEUTRALIZATION OF HEPAMIN | SQUIBB & SONS INC (US) | 1993-08-04 | — | — | EP | claimed |
| EP-0340008-B1 | METHOD OF PREVENTING OR REDUCING VENOUS THROMBOSIS USING A THROMBOXANE A2 RECEPTOR ANTAGONIST IN CONJUNCTION WITH HEPARIN AND COMBINATION | SQUIBB & SONS INC (US) | 1992-10-14 | — | — | EP | claimed |
| US-5066480-A | Treating pulmonary hypertension caused by protamine induced neutralization of heparin | E. R. SQUIBB & SONS, INC. (US) | 1991-11-19 | — | — | US | claimed |
| EP-0448274-A2 | Use of a thromboxane A2 receptor antagonist for the manufacture of a medicament for the treatment of ulcerative gastrointestinal conditions | E.R. SQUIBB & SONS, INC. (US) | 1991-09-25 | — | — | EP | claimed |
| US-4931460-A | ADMINISTERING 7-OXA-BICYLOHEPTANE PROSTAGLANDIN ANALOGS | E. R. SQUIBB & SONS, INC. (US) | 1990-06-05 | — | — | US | claimed |
| US-4900723-A | Method of preventing or reducing venous thrombosis using a thromboxane A2 receptor antagonist in conjunction with heparin and combination | E. R. SQUIBB & SONS, INC. (US) | 1990-02-13 | — | — | US | claimed |
| EP-0340008-A1 | Method of preventing or reducing venous thrombosis using a thromboxane A2 receptor antagonist in conjunction with heparin and combination | E.R. SQUIBB & SONS, INC. (US) | 1989-11-02 | — | — | EP | claimed |
| EP-0337697-A2 | Use of a thromboxane A2 receptor antagonist for the manufacture of a medicament for treating pulmonary hypertension caused by protamine induced neutralization of hepamin | E.R. SQUIBB & SONS, INC. (US) | 1989-10-18 | — | — | EP | claimed |
| EP-0332306-A2 | Preventing platelet loss using a thromboxane A2 receptor antagonist | E.R. Squibb & Sons, Inc. (US) | 1989-09-13 | — | — | EP | claimed |
| EP-0320935-A2 | Method of preventing or treating toxemia in pregnancy using a thromboxane A2 receptor antagonist | E.R. Squibb & Sons, Inc. (US) | 1989-06-21 | — | — | EP | claimed |
| US-4820733-A | WITH PROSTACYCLIN OR PROSTACYCLIN MIMIC | E.R. SQUIBB & SONS, INC. (US) | 1989-04-11 | — | — | US | claimed |
| EP-0309801-A2 | Use of thromboxane A2 antagonists for the manufacture of a medicament for improving post-ischemic myocardial dysfunction | E.R. Squibb & Sons, Inc. (US) | 1989-04-05 | — | — | EP | claimed |
| US-4808627-A | Method of preventing or treating toxemia in pregnancy using a thromboxane A2 receptor antagonist | E. R. SQUIBB & SONS, INC. (US) | 1989-02-28 | — | — | US | claimed |
| JP-1199914-A | — | — | None | — | — | JP | disclosed |
| US-20250114334-A1 | Ifetroban Treatment for Systemic Sclerosis | VANDERBILT UNIVERSITY | 2025-04-10 | — | — | US | disclosed |
| US-20250049764-A1 | Compositions and Methods of Treating Cardiac Fibrosis with Ifetroban | CUMBERLAND PHARMACEUTICALS INC. | 2025-02-13 | — | — | US | disclosed |
| US-4220594-A | Hexa- and octahydro-4,7-epoxyisobenzofuran-1-ol and hexa- and octahydro-5,8-epoxy-1H-2-benzopyran-3-ol | E. R. SQUIBB & SONS, INC. (US) | 1980-09-02 | — | — | US | disclosed |
| US-4143054-A | 7-OXABICYCLOHEPTANE- AND 7-OXABICYCLOHEPTENE COMPOUNDS | E. R. SQUIBB & SONS, INC. (US) | 1979-03-06 | — | — | US | disclosed |
| US-4143054-A | 7-OXABICYCLOHEPTANE- AND 7-OXABICYCLOHEPTENE COMPOUNDS | E. R. SQUIBB & SONS, INC. (US) | 1979-03-06 | — | — | US | disclosed |